RetinalGeniX Technologies focuses on prevention of blindness, early detection of multiple systemic diseases
EyeSouth Partners has partnered with Retina and Vitreous of Texas, a retina-only practice in Houston, Texas. The company’s current network encompasses 38 practices and over 300 doctors who deliver medical and surgical eye care services across more than 180 locations.
More than 135 patients have been recruited in 4 months for Phase 2 study of a single intravitreal (IVT) injection of ONL1204 ophthalmic solution as an adjunct to standard-of-care surgery.
The 3D viewing systems and digital microscopes offer numerous advantages for performing the procedures.
Maria H. Berrocal spoke with our team about her presentation at the Women in Ophthalmology Summer Symposium being held in Marco Island, Florida.
The FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date for APP13007 of March 4, 2024.
Clinicians should be alert to the fact that while artificial intelligence (AI) is capable of generating ideas and references, it is crucial to thoroughly vet and fact-check any medical research content that AI produces.
According to Orbis International, the technology proves to be a practical solution in low-resource communities for tackling the leading cause of vision loss among working-age adults.
The plan is intended to upgrade Vitagrus’ manufacturing process so that it can ultimately handle the global market supply.
In this study, the investigators retrospectively reviewed all study patients who underwent pars plana vitrectomy with silicone oil tamponade for postsurgical endophthalmitis.
Oculis Holding AG announced, if approved, OCS-01 has the potential to become a new standard of care as the first once-daily, topical, preservative-free corticosteroid for treating inflammation and pain following ocular surgery.
J. Fernando Arevalo, MD, PhD, FACS, FASRS, a member of Modern Retina's editorial advisory board, spoke with us about clinical characteristics of macular holes that close without surgery.
The Modern Retina team caught up with one of our board members, Fernando Arevalo, MD, PhD, FACS, FASRS, who shared information on his presentation on the treatment of progressively symptomatic retinal detachments associated with retinoschisis cases at the 2023 ASRS annual meeting.
Matthew R. Starr, MD, discusses how secondary lens techniques have changed over time.
Richard B. Rosen, MD, shared insights from his presentation from ASRS 2023 on "New 'MacGyver-inspired' endolaser option for chandelier-assisted scleral buckles" with Sheryl Stevenson, our Group Editorial Director.
The companies plant to create a comprehensive resource that provides valuable insights into health outcomes, medication adherence, and the effectiveness of various treatment protocols.
Vantage Surgical Solutions has acquired Ophthalmic Surgical Solutions (OSS). OSS is a Kansas-based company specializing in ophthalmic surgical equipment and services.
In-person and virtual trainings, coupled with the support of local product representatives, are the best ways to ensure retina specialists are set up for success.
Dr Jennifer Lim presents two case studies demonstrating the application of the personalized treatment interval algorithm from the YOSEMITE and RHINE clinical trials for faricimab in DME.
Dr Jennifer Lim reviews the personalized treatment algorithm in the YOSEMITE and RHINE trials for faricimab in DME, discussing visual and anatomic outcomes with the treat and extend strategy.
Artificial intelligence (AI) is going to be highly instrumental in patient care in all medical specialties and will be highly relevant in eye care.
Early clinical studies indicate that Vitargus® has unique properties that could eliminate the need for patients to remain face-down after retinal detachment and vitreous hemorrhage surgery.
With the newly modified lighted endolaser probe, an 18-gauge angiocatheter sleeve protects against vitreous disturbance.
The presentations highlighted the Clearside Biomedical’s efforts in suprachoroidal delivery of agents to the back of the eye.
Dr Ong and colleagues undertook a retrospective study of patients who underwent primary repair of uncomplicated RRDs at the Wilmer Eye Institute to examine the baseline, surgical, and postoperative characteristics that affect best-corrected VA (BCVA) outcomes.
Sally S. Ong, MD, shares the key takeaways from her presentation, Predictors of Poor Visual Outcome After Repair of Uncomplicated Rhegmatogenous Retinal Detachments, at the 11th Annual Vit-Buckle Society meeting.
